Showing 101–125 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Anushka Naidoo, PhD, Kelly Dooley, MD, Kogieleum Naidoo, PhD
…the activity of Bictegravir and dolutegravir-containing ART regimens in patients with drug-susceptible TB through 48 weeks Primary objective: To characterize viral suppression rates (proportion of patients with suppressed viral load) at week 24 in the BIC arm Secondary objectiv…
Nhat Linh Nguyen, Fuad Mirzayev, Kerri Viney, Medea Gegia, Matteo Zignol
<b>Background:</b> Recent developments in TB treatment have prompted the need for revision of the TB treatment outcome definitions. <b>Aims and objectives:</b> The objectives of the WHO consultation were to determine recent changes in TB treatment affecting treatment outcome defi…
Anna Turkova, Genevieve H. Wills, Eric Wobudeya, Chishala Chabala, Megan Palmer, et al.
BACKGROUND: \nTwo thirds of children with tuberculosis have nonsevere disease, which may be treatable with a shorter regimen than the current 6-month regimen. \n \nMETHODS: \nWe conducted an open-label, treatment-shortening, noninferiority trial involving childr…
Ngo HX, Xu AY, Velásquez GE, Zhang N, Chang VK, et al.
Background The optimal dosing strategy for rifampicin in treating drug-susceptible tuberculosis (TB) is still highly debated. In the phase 3 clinical trial Study 31/ACTG 5349 (NCT02410772), all participants in the control regimen arm received 600 mg rifampicin daily as a flat dos…
Ryuk DK, Pelissari DM, Alves K, Oliveira PB, Castro MC, et al.
Introduction Tuberculosis (TB) causes over 1 million deaths annually. Providing effective treatment is a key strategy for reducing TB deaths. In this study, we identified factors associated with unsuccessful treatment outcomes among individuals treated for TB in Brazil. Methods W…
Chimeh RA, Gafar F, Pradipta IS, Akkerman OW, Hak E, et al.
…on goals are falling behind. While non-adherence to TB drug regimens may compromise effective treatment, its full impact is still unknown. OBJECTIVE: To determine the clinical and economic impact of non-adherence to TB medication on treatment outcomes in drug-susceptible TB patie…
Hamu J Mlyuka, Alphonce Liyoyo, Belinda Nyaulingo, Emmanuel Mpolya, Oscar L Kaswaga, et al.
**BACKGROUND:** Current combination antibiotic treatment for drug-susceptible tuberculosis (DS-TB) usually takes 6 months to complete. This long duration can compromise clinical outcomes. Although a 4-month regimen including an optimized dose of rifapentine plus moxifloxacin is n…
Cicchese JM, Dartois V, Kirschner DE, Linderman JJ
…6 months of antibiotics. Factors that contribute to lengthy regimens include antibiotic underexposure in lesions due to poor pharmacokinetics (PK) and complex granuloma compositions, but it is difficult to quantify how individual antibiotics are affected by these factors and to w…
Hirsch-Moverman Y, Mantell JE, Lebelo L, Wynn C, Hesseling AC, et al.
Background Shorter-duration regimens for preventing drug-susceptible tuberculosis (TB) have been shown to be safe and efficacious in children, and may improve acceptability, adherence, and treatment completion. While these regimens have been used in children in low TB burden coun…
Shangguan Y, Guo W, Feng X, Shi Y, Li X, et al.
Objectives Faropenem has antituberculosis activity in vitro but its utility in treating patients with tuberculosis (TB) is unclear. Methods We conducted an open-label, randomized trial in China, involving newly diagnosed, drug-susceptible pulmonary TB. The control group was treat…
Finlayson H, Lishman J, Palmer M
…e continued. The WHO now recommends shorter rifamycin-based regimens for TB preventive treatment as well as shorter regimens for the treatment of both drug-susceptible and drug-resistant TB. The Xpert Ultra assay is now recommended as the initial diagnostic test for TB in childre…
World Health Organization
…t TB and re-registration of patients starting new treatment regimens. It highlights the relationship between individual patient records and aggregated surveillance reporting, supporting consistent interpretation and application of WHO surveillance definitions and reporting standa…
World Health Organization
…pproaches, with particular emphasis on optimizing treatment regimens for drug-susceptible TB through shorter, safer and more person-centred therapies. Participants discussed candidate regimens, comparator treatments, inclusion of populations often underrepresented in clinical tri…
V Shukatka, L Skoklyuk, M Germanovych, A Bogdanov, T Ivanenko, et al.
…acts. DS-TB contacts were offered shorter rifapentine-based regimens, while DR-TB contacts received levofloxacin. Implementation challenges were addressed through training and mentorship. **CONCLUSION:** Ukraine's implementation of QFT-Plus testing and shorter TPT regimens marks…
Gallagher SK, Wang J, Lumbard K, Dodd LE, Proschan M
The PREDICT TB trial tests noninferiority of an abbreviated treatment regimen (arm A) vs a conventional treatment regimen (arm C). Treatment trials of drug-susceptible tuberculosis are expected to have low event rates (ie, relapse probabilities around 3-5%). We examine the questi…
O.M. Shvets, О.С. Шевченко, Liliia D. TODORIKO, Olena Tovazhnyanska, Olga I. DUBYNSKA, et al.
The objective of the study was to assess the development of peripheral neuropathy in patients with newly diagnosed pulmonary tuberculosis during the treatment with first- and second-line antitubercular drugs, by studying the changes of plasma vitamin B1 and vitamin B12 levels. Ma…
Aner H Khan
…ow tolerability, and extended duration of current treatment regimens, especially for both drug-susceptible and drug-resistant TB. There is a need for continuing the quest for low-cost, reliable, and acceptable measures of adherence for the treatment of TB and HIV co-infection. A …
Malaisamy Muniyandi, Karikalan Nagarajan
… in lowincome and middle-income countries, and thus shorter regimens for both drug-susceptible and drug-resistant tuberculosis are vital.
Mukunda Prasad Kafle
Treatment of Mycobacterium tuberculosis infection (tuberculosis disease) involves the use of multiple antimicrobials over several months. Therapy directed against tuberculosis (anti-tubercular therapy, or ATT) consists of rifampicin and isoniazid given daily for 6 months and pyra…
Ekqvist D, Bornefall A, Augustinsson D, Sönnerbrandt M, Nordvall MJ, et al.
Introduction Increased dosing of rifampicin and pyrazinamide seems a viable strategy to shorten treatment and prevent relapse of drug-susceptible tuberculosis (TB), but safety and efficacy remains to be confirmed. This clinical trial aims to explore safety and pharmacokinetics-ph…
Kohler S, Achar J, Mulder C, Sitali N, Paul N
…ombinations (9 API combinations), and 8 patient kits (8 API regimens and other materials). The number of TB drugs listed in the GDF Product Catalog increased from 9 (8 APIs) to 55 (32 APIs). The price decreased for 17, increased for 19, and showed no trend for 12 APIs. The price …
Somoskovi A, Salfinger M
In 2019, tuberculosis is still a global source of morbidity and mortality. To determine and provide the most effective treatment regimen to patients, the tuberculosis laboratory needs to rapidly but reliably answer 2 main questions: (1) Is Mycobacterium tuberculosis detectable in…
Xu AY, Velásquez GE, Zhang N, Chang VK, Phillips PPJ, et al.
Rationale: Optimizing pyrazinamide dosing is critical to improve treatment efficacy while minimizing toxicity during tuberculosis treatment. Study 31/AIDS Clinical Trials Group A5349 represents the largest phase 3 randomized controlled therapeutic trial to date for such an invest…
Nie W, Wang J, Zeng J, Wang Q, Du Y, et al.
Purpose Evaluation of the efficacy and safety of IL-2 in the treatment of drug-susceptible tuberculosis. Methods First, the cases of diagnosed drug-susceptible tuberculosis were randomized into two groups-the control group that received the background regimen of isoniazid, rifamp…
Zha BS, Nahid P
…ongoing tuberculosis transmission. To achieve durable cure, regimens must include multiple agents given concurrently and in a manner to ensure completion of therapy. This article focuses on preferred regimens of drug-susceptible tuberculosis under current guidelines by the Americ…